Patients with premenstrual dysphoric disorder have increased startle modulation during anticipation in the late luteal phase period in comparison to control subjects

Psychoneuroendocrinology

Volumn 36, Issue 8, 2011, Pages 1184-1192

  Bannbers, Elin ^a   Kask, Kristiina ^a   Wikström, Johan ^a   Risbrough, Victoria ^b   Sundström Poromaa, Inger ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Estradiol; Menstrual cycle; Premenstrual dysphoric disorder; Progesterone; Startle response

Indexed keywords

ESTRADIOL; PROGESTERONE;

ADULT; ANTICIPATION; AROUSAL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ELECTROMYOGRAM; EMOTION; ESTRADIOL BLOOD LEVEL; FEMALE; FOLLICULAR PHASE; HUMAN; LUTEAL PHASE; NEUROMODULATION; PREMENSTRUAL DYSPHORIC DISORDER; PRIORITY JOURNAL; PROGESTERONE BLOOD LEVEL; STARTLE REFLEX;

ADULT; ANTICIPATION, PSYCHOLOGICAL; FEMALE; HUMANS; LUTEAL PHASE; PHOTIC STIMULATION; PREMENSTRUAL SYNDROME; RESEARCH DESIGN; SELF-ASSESSMENT; STARTLE REACTION; TIME FACTORS; UP-REGULATION; YOUNG ADULT;

EID: 80051469071     PISSN: 03064530     EISSN: 18733360     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2011.02.011     Document Type: Article

References (42)

1. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 1994, American Psychiatric Association, Washington, DC. fourth ed.
2. Baas J.M., Mol N., Kenemans J.L., Prinssen E.P., Niklson I., Xia-Chen C., Broeyer F., van Gerven J. Validating a human model for anxiety using startle potentiated by cue and context: the effects of alprazolam, pregabalin, and diphenhydramine. Psychopharmacology (Berl.) 2009, 205:73-84.
3. Bixo M., Andersson A., Winblad B., Purdy R.H., Backstrom T. Progesterone, 5alpha-pregnane-3,20-dione and 3alpha-hydroxy-5alpha-pregnane-20-one in specific regions of the human female brain in different endocrine states. Brain Res. 1997, 764:173-178.
4. Blumenthal T.D., Cuthbert B.N., Filion D.L., Hackley S., Lipp O.V., van Boxtel A. Committee report: guidelines for human startle eyeblink electromyographic studies. Psychophysiology 2005, 42:1-15.
5. Brody S.A., Dulawa S.C., Conquet F., Geyer M.A. Assessment of a prepulse inhibition deficit in a mutant mouse lacking mGlu5 receptors. Mol. Psychiatry 2004, 9:35-41.
6. Brown J., O'Brien P.M., Marjoribanks J., Wyatt K. Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database Syst. Rev. 2009, CD001396.
7. Cronje W.H., Vashisht A., Studd J.W. Hysterectomy and bilateral oophorectomy for severe premenstrual syndrome. Hum. Reprod. 2004, 19:2152-2155.
8. Cunningham J., Yonkers K.A., O'Brien S., Eriksson E. Update on research and treatment of premenstrual dysphoric disorder. Harv. Rev. Psychiatry 2009, 17:120-137.
9. Davis M. Neural systems involved in fear and anxiety measured with fear-potentiated startle. Am. Psychol. 2006, 61:741-756.
10. Dichter G.S., Tomarken A.J., Baucom B.R. Startle modulation before, during and after exposure to emotional stimuli. Int. J. Psychophysiol. 2002, 43:191-196.
11. Epperson C.N., Pittman B., Czarkowski K.A., Stiklus S., Krystal J.H., Grillon C. Luteal-phase accentuation of acoustic startle response in women with premenstrual dysphoric disorder. Neuropsychopharmacology 2007, 32:2190-2198.
12. Etkin A., Wager T.D. Functional neuroimaging of anxiety: a meta-analysis of emotional processing in PTSD, social anxiety disorder, and specific phobia. Am. J. Psychiatry 2007, 164:1476-1488.
13. Grillon C., Baas J. A review of the modulation of the startle reflex by affective states and its application in psychiatry. Clin. Neurophysiol. 2003, 114:1557-1579.
14. Gulinello M., Orman R., Smith S.S. Sex differences in anxiety, sensorimotor gating and expression of the alpha4 subunit of the GABAA receptor in the amygdala after progesterone withdrawal. Eur. J. Neurosci. 2003, 17:641-648.
15. Hammarbäck S., Bäckström T., MacGibbon-Taylor B. Diagnosis of premenstrual tension syndrome: description and evaluation of a procedure for diagnosis and differential diagnosis. J. Psychosom. Obstet. Gynaecol. 1989, 10:25-42.
16. Hsieh M.H., Swerdlow N.R., Braff D.L. Effects of background and prepulse characteristics on prepulse inhibition and facilitation: implications for neuropsychiatric research. Biol. Psychiatry 2006, 59:555-559.
17. Kask K., Backstrom T., Lundgren P., Sundstrom Poromaa I. Allopregnanolone has no effect on startle response and prepulse inhibition of startle response in patients with premenstrual dysphoric disorder or healthy controls. Pharmacol. Biochem. Behav. 2009, 92:608-613.
18. Kask K., Gulinello M., Backstrom T., Geyer M.A., Sundstrom-Poromaa I. Patients with premenstrual dysphoric disorder have increased startle response across both cycle phases and lower levels of prepulse inhibition during the late luteal phase of the menstrual cycle. Neuropsychopharmacology 2008, 33:2283-2290.
19. Kaviani H., Gray J.A., Checkley S.A., Raven P.W., Wilson G.D., Kumari V. Affective modulation of the startle response in depression: influence of the severity of depression, anhedonia, and anxiety. J. Affect. Disord. 2004, 83:21-31.
20. Lang P.J., Bradley M.M., Cuthbert B.N. International Affective Picture System (IAPS): Affective Ratings of Pictures and Instruction Manual. Technical Report A-6 2005, University of Florida, Gainsville, FL.
21. Lang P.J., Davis M., Ohman A. Fear and anxiety: animal models and human cognitive psychophysiology. J. Affect. Disord. 2000, 61:137-159.
22. Melzig C.A., Weike A.I., Zimmermann J., Hamm A.O. Startle reflex modulation and autonomic responding during anxious apprehension in panic disorder patients. Psychophysiology 2007, 44:846-854.
23. Montgomery S.A., Asberg M. A new depression scale designed to be sensitive to change. Br. J. Psychiatry 1979, 134:382-389.
24. Nitschke J.B., Larson C.L., Smoller M.J., Navin S.D., Pederson A.J., Ruffalo D., Mackiewicz K.L., Gray S.M., Victor E., Davidson R.J. Startle potentiation in aversive anticipation: evidence for state but not trait effects. Psychophysiology 2002, 39:254-258.
25. Ostlund H., Keller E., Hurd Y.L. Estrogen receptor gene expression in relation to neuropsychiatric disorders. Ann. N. Y. Acad. Sci. 2003, 1007:54-63.
26. Paulus M.P., Stein M.B. An insular view of anxiety. Biol. Psychiatry 2006, 60:383-387.
27. Pearlstein T. Premenstrual dysphoric disorder: out of the appendix. Arch. Womens Ment. Health 2010, 13:21-23.
28. Pissiota A., Frans O., Michelgard A., Appel L., Langstrom B., Flaten M.A., Fredrikson M. Amygdala and anterior cingulate cortex activation during affective startle modulation: a PET study of fear. Eur. J. Neurosci. 2003, 18:1325-1331.
29. Protopopescu X., Tuescher O., Pan H., Epstein J., Root J., Chang L., Altemus M., Polanecsky M., McEwen B., Stern E., Silbersweig D. Toward a functional neuroanatomy of premenstrual dysphoric disorder. J. Affect. Disord. 2008, 108:87-94.
30. Sabatinelli D., Bradley M.M., Lang P.J. Affective startle modulation in anticipation and perception. Psychophysiology 2001, 38:719-722.
31. Saleh T.M., Connell B.J., Cribb A.E. Sympathoexcitatory effects of estrogen in the insular cortex are mediated by GABA. Brain Res. 2005, 1037:114-122.
32. Schmidt P.J., Nieman L.K., Danaceau M.A., Adams L.F., Rubinow D.R. Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome. N. Engl. J. Med. 1998, 338:209-216.
33. Schmidt P.J., Nieman L.K., Grover G.N., Muller K.L., Merriam G.R., Rubinow D.R. Lack of effect of induced menses on symptoms in women with premenstrual syndrome. N. Engl. J. Med. 1991, 324:1174-1179.
34. Segebladh B., Borgstrom A., Nyberg S., Bixo M., Sundstrom-Poromaa I. Evaluation of different add-back estradiol and progesterone treatments to gonadotropin-releasing hormone agonist treatment in patients with premenstrual dysphoric disorder. Am. J. Obstet. Gynecol. 2009, 201:e131-138.
35. Sheehan D.V., Lecrubier Y., Sheehan K.H., Amorim P., Janavs J., Weiller E., Hergueta T., Baker R., Dunbar G.C. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin. Psychiatry 1998, 59(Suppl. 20). 22-33;quiz 34-57.
36. Simmons A., Strigo I., Matthews S.C., Paulus M.P., Stein M.B. Anticipation of aversive visual stimuli is associated with increased insula activation in anxiety-prone subjects. Biol. Psychiatry 2006, 60:402-409.
37. Simmons A.N., Arce E., Lovero K.L., Stein M.B., Paulus M.P. Subchronic SSRI administration reduces insula response during affective anticipation in healthy volunteers. Int. J. Neuropsychopharmacol. 2009, 12:1009-1020.
38. Simmons A.N., Paulus M.P., Thorp S.R., Matthews S.C., Norman S.B., Stein M.B. Functional activation and neural networks in women with posttraumatic stress disorder related to intimate partner violence. Biol. Psychiatry 2008, 64:681-690.
39. Spielberger C.D. Stait-Trait Anxiety Inventory for Adults. Sampler Set, Manual Set, Scoring Key 1983, Consulting Psychologists Press Inc., Palo Alto.
40. Sundstrom I., Nyberg S., Bixo M., Hammarback S., Backstrom T. Treatment of premenstrual syndrome with gonadotropin-releasing hormone agonist in a low dose regimen. Acta Obstet. Gynecol. Scand. 1999, 78:891-899.
41. Toufexis D.J., Davis C., Hammond A., Davis M. Progesterone attenuates corticotropin-releasing factor-enhanced but not fear-potentiated startle via the activity of its neuroactive metabolite, allopregnanolone. J. Neurosci. 2004, 24:10280-10287.
42. Vollenweider F.X., Csomor P.A., Knappe B., Geyer M.A., Quednow B.B. The effects of the preferential 5-HT2A agonist psilocybin on prepulse inhibition of startle in healthy human volunteers depend on interstimulus interval. Neuropsychopharmacology 2007, 32:1876-1887.